LGND Stock Overview
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Ligand Pharmaceuticals Incorporated Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$58.75 |
| 52 Week High | US$85.70 |
| 52 Week Low | US$49.24 |
| Beta | 0.81 |
| 1 Month Change | 10.23% |
| 3 Month Change | -11.71% |
| 1 Year Change | -19.14% |
| 3 Year Change | -32.13% |
| 5 Year Change | -59.65% |
| Change since IPO | -2.09% |
Recent News & Updates
Recent updates
Is Now The Time To Put Ligand Pharmaceuticals (NASDAQ:LGND) On Your Watchlist?
Jun 14
We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt
May 29Are Investors Undervaluing Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) By 45%?
May 07These 4 Measures Indicate That Ligand Pharmaceuticals (NASDAQ:LGND) Is Using Debt Reasonably Well
Jan 26We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt
Oct 21Ligand Pharmaceuticals: Struggling Along
Sep 25Growth Investors: Industry Analysts Just Upgraded Their Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Revenue Forecasts By 11%
Aug 11Here's Why Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt Responsibly
Jun 27Ligand Pharmaceuticals: Moving Parts Keep Moving
Mar 29We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt With Ease
Mar 17Ligand: Green Shoots And A Hidden Treasure - A Spinoff Bonus For The New Year
Dec 31Is Ligand Pharmaceuticals (NASDAQ:LGND) A Risky Investment?
Dec 03Is Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Trading At A 38% Discount?
Oct 11Ligand's Ailing Remdesivir Cash Cow
Oct 11Is Ligand Pharmaceuticals (NASDAQ:LGND) A Risky Investment?
Aug 19Ligand: 2021 Is Pivotal
Jul 16Calculating The Fair Value Of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
Jun 25Here's Why Shareholders May Want To Be Cautious With Increasing Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) CEO Pay Packet
May 29Ligand Pharmaceuticals Incorporated Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
May 06Shareholder Returns
| LGND | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -2.2% | -0.3% | 1.1% |
| 1Y | -19.1% | -4.5% | 11.9% |
Return vs Industry: LGND underperformed the US Pharmaceuticals industry which returned -4% over the past year.
Return vs Market: LGND underperformed the US Market which returned 11% over the past year.
Price Volatility
| LGND volatility | |
|---|---|
| LGND Average Weekly Movement | 4.6% |
| Pharmaceuticals Industry Average Movement | 10.8% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: LGND is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: LGND's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 76 | Todd Davis | https://www.ligand.com |
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression.
Ligand Pharmaceuticals Incorporated Fundamentals Summary
| LGND fundamental statistics | |
|---|---|
| Market Cap | US$1.02b |
| Earnings (TTM) | US$21.10m |
| Revenue (TTM) | US$153.60m |
48.6x
P/E Ratio6.7x
P/S RatioIs LGND overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LGND income statement (TTM) | |
|---|---|
| Revenue | US$153.60m |
| Cost of Revenue | US$58.73m |
| Gross Profit | US$94.86m |
| Other Expenses | US$73.77m |
| Earnings | US$21.10m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.21 |
| Gross Margin | 61.76% |
| Net Profit Margin | 13.74% |
| Debt/Equity Ratio | 0% |
How did LGND perform over the long term?
See historical performance and comparison